|NEWSRoom | Source: PCORI|
PCORI and AHRQ Partner on Request for Applications to Study Treatments for Uterine Fibroids
The Patient-Centered Outcomes Research Institute (PCORI) and the Agency for Healthcare Research and Quality (AHRQ) have partnered on the release of a Request for Applications (RFA) for research designed to evaluate the effectiveness of different treatment strategies for uterine fibroids and to better understand patient preference in informing treatment decisions.
In partnership with AHRQ, PCORI will commit up to $20 million to develop a geographically diverse registry of women who have been treated for uterine fibroids and fund studies of the comparative effectiveness of medical and surgical therapies using data from this registry. AHRQ will administer the application process to identify an awardee who will receive up to $4 million per year for up to five years to build the registry and conduct the research.
Uterine fibroids are noncancerous growths in the uterus that affect up to 10% of women of childbearing age. Although they often occur without symptoms, they can lead to significant pain, bleeding, and fertility problems. In 2007, more than 260,000 women with uterine fibroids underwent hysterectomies.
Because there is little evidence about the relative effectiveness of the therapies used to manage symptoms and address patients’ preferences for reproductive options, women and their clinicians often face significant uncertainties when deciding on a course of treatment. PCORI and AHRQ agreed earlier this year to collaborate on research to address these uncertainties and answer patients’ questions about potential implications for their ability to bear children as well as other risks and benefits.
“This initiative, which will generate critical information about the comparative benefits and risks of the medical and surgical options used to treat uterine fibroids, is an excellent illustration of the kind of patient-centered comparative effectiveness research that PCORI funds,” said PCORI Executive Director Joe Selby, MD, MPH. “We are excited to work with our colleagues at AHRQ to produce new evidence that will help women, their families, and their healthcare providers make better-informed choices.”
The RFA calls for development of a large, multi-center, practice-based registry of women who have been treated for uterine fibroids. The registry must be geographically broad to ensure the inclusion of women from diverse backgrounds as well as those who traditionally have been less involved in health research. The collection of privacy-protected, real-world information on women’s experiences with different treatments will allow the conduct of a range of studies comparing patient-centered clinical outcomes.
Letters of intent may be submitted to AHRQ by Friday, November 15 and applications are due Monday, December 16. The due date has not been affected by the federal government shutdown. Eligibility requirements, application criteria, informational contacts at AHRQ, and other details are provided in the RFA.
|Short Link: http://www.news-line.com/?s151283|
comments powered by Disqus